Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCEL NASDAQ:NEUP NASDAQ:NXTC NASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCELAtreca$0.09$0.09$0.05▼$1.20$3.57M1.034.61 million shsN/ANEUPNeuphoria Therapeutics$11.33-7.2%$7.76$2.12▼$13.34$22.96M0.5353,452 shs125,912 shsNXTCNextCure$5.03-1.9%$5.18$2.69▼$19.20$13.73M1.2521,522 shs5,856 shsPRPHProPhase Labs$0.34-2.4%$0.37$0.22▼$3.00$14.39M-0.4815.30 million shs259,758 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCELAtreca0.00%0.00%0.00%0.00%0.00%NEUPNeuphoria Therapeutics-7.21%+57.80%+38.85%+72.98%+1,132,999,900.00%NXTCNextCure-1.95%-1.95%+0.40%-13.45%-73.47%PRPHProPhase Labs-2.42%+2.83%-5.00%-10.77%-85.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCELAtrecaN/AN/AN/AN/AN/AN/AN/AN/ANEUPNeuphoria Therapeutics2.0101 of 5 stars3.50.00.00.03.10.00.6NXTCNextCure4.4376 of 5 stars3.33.00.04.33.31.71.3PRPHProPhase Labs1.4333 of 5 stars0.05.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCELAtreca 0.00N/AN/AN/ANEUPNeuphoria Therapeutics 3.00Buy$21.0085.35% UpsideNXTCNextCure 2.67Moderate Buy$25.50406.96% UpsidePRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BCEL, PRPH, NXTC, and NEUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025NEUPNeuphoria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.007/15/2025NXTCNextCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOverweight ➝ Overweight$36.00 ➝ $15.007/8/2025NXTCNextCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold7/1/2025NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCELAtrecaN/AN/AN/AN/A$2.01 per shareN/ANEUPNeuphoria Therapeutics$10K2,130.04N/AN/A$15.85 per share0.71NXTCNextCureN/AN/AN/AN/A$11.82 per shareN/APRPHProPhase Labs$6.77M2.07N/AN/A$0.28 per share1.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCELAtreca-$97.16M-$2.50N/AN/AN/AN/A-157.90%-71.39%N/ANEUPNeuphoria Therapeutics-$15.49MN/A0.00N/AN/AN/AN/AN/A9/29/2025 (Estimated)NXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-262.42%-76.48%11/12/2025 (Estimated)Latest BCEL, PRPH, NXTC, and NEUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PRPHProPhase Labs-$0.15-$0.11+$0.04-$0.11$3.55 million$1.25 million8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCELAtrecaN/AN/AN/AN/AN/ANEUPNeuphoria TherapeuticsN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCELAtrecaN/A1.581.58NEUPNeuphoria TherapeuticsN/A11.0111.01NXTCNextCureN/A3.713.71PRPHProPhase Labs0.200.960.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCELAtreca37.47%NEUPNeuphoria Therapeutics15.90%NXTCNextCure42.65%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipBCELAtreca11.30%NEUPNeuphoria Therapeutics0.69%NXTCNextCure17.90%PRPHProPhase Labs9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCELAtreca13039.62 million35.15 millionOptionableNEUPNeuphoria TherapeuticsN/A1.88 million1.87 millionN/ANXTCNextCure902.68 million2.20 millionOptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableBCEL, PRPH, NXTC, and NEUP HeadlinesRecent News About These CompaniesProPhase Labs, Inc. (PRPH) Q2 2025 Earnings Call TranscriptAugust 20, 2025 | seekingalpha.comProPhase Labs files definitive proxy statement for special meetingAugust 20, 2025 | msn.comProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of ShareholdersAugust 19, 2025 | globenewswire.comProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future ProspectsAugust 15, 2025 | finance.yahoo.comProPhase Labs Reports Turnaround and Strategic GrowthAugust 14, 2025 | msn.comProPhase Labs Posts Narrower Q2 LossAugust 13, 2025 | aol.comAProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025August 13, 2025 | globenewswire.comProPhase Labs stock soars after securing patent for esophageal disease testAugust 12, 2025 | investing.comEarnings Preview For ProPhase LabsAugust 12, 2025 | benzinga.comProPhase Labs Shares Surge 38% Following Patent Approval for Esophageal Disease TestAugust 12, 2025 | msn.comWhy Is ProPhase Labs Stock (PRPH) Up 25% Today?August 12, 2025 | msn.comProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk AssessmentAugust 12, 2025 | globenewswire.comProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025August 11, 2025 | globenewswire.comProPhase Labs Appoints New Fractional CFOAugust 6, 2025 | tipranks.comProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy StatementJuly 29, 2025 | globenewswire.comProPhase Labs announces closing of $3M senior secured convertible notesJuly 25, 2025 | msn.comProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes FinancingJuly 23, 2025 | globenewswire.comProPhase Labs Board of Directors Authorizes Management to Explore Strategic Reverse Merger and Approves Crypto Treasury InitiativeJuly 21, 2025 | globenewswire.comProPhase Labs Regains Nasdaq Compliance with New AppointmentJuly 1, 2025 | tipranks.comProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule - MorningstarJune 27, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCEL, PRPH, NXTC, and NEUP Company DescriptionsAtreca NASDAQ:BCELAtreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.Neuphoria Therapeutics NASDAQ:NEUP$11.33 -0.88 (-7.21%) As of 08/29/2025 04:00 PM EasternNeuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.NextCure NASDAQ:NXTC$5.03 -0.10 (-1.95%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$5.15 +0.12 (+2.39%) As of 08/29/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.ProPhase Labs NASDAQ:PRPH$0.34 -0.01 (-2.42%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.33 -0.01 (-2.10%) As of 08/29/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
